← All trials
NCT04294277
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 14, 2020
- Primary completion
- Dec 14, 2022
- Completion date
- Mar 14, 2023
- First posted
- Mar 4, 2020
- Last posted
- Mar 4, 2020
- Enrollment
- 56
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- European Association of Urology Research FoundationLead sponsor
- Advanced Medical Services GmbHCollaborator
- IncyteCollaborator
- High Research s.r.l.Collaborator
- IRCCS Istituto Nazionale dei TumoriOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.